Skip to main content

Table 2 Associations between ITF2 methylation and clinicopathological features in tumor DNA. Analysis of 216 MSI-H and 216 MSS CRC patients from Ontario and Newfoundland

From: Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients

  MSS (n = 216) MSI-H (n = 216)
  Unmethylated (%) Methylated (%) OR (95 % CI)a P-value Unmethylated (%) Methylated (%) OR (95 % CI)a P-value
Age         
 <50 24 (15.2) 6 (10.3) 1.552 (0.600–4.014) 0.361 24 (20.5) 14 (14.1) 1.567 (0.761–3.225) 0.220
 50+ 134 (84.8) 52 (89.7)    93 (79.5) 85 (85.9)   
Sex         
 Male 73 (46.2) 26 (44.8) 1.057 (0.577–1.935) 0.857 64 (54.7) 36 (36.4) 2.113 (1.222–3.655) 0.007
 Female 85 (53.8) 32 (55.2)    53 (45.3) 63 (63.6)   
TNM Stageb         
 1 36 (22.8) 14 (24.1) 0.720 (0.606–0.856) 0.193 31 (26.5) 18 (18.2) 5.167 (0.499–53.450) 0.321
 2 78 (49.4) 32 (55.2)    57 (48.7) 55 (55.6)   
 3 32 (20.3) 12 (20.7)    28 (23.9) 23 (23.2)   
 4 12 (7.6) 0 (0.0)    1 (0.9) 3 (3.0)   
Histological Gradeb         
 Low 16 (10.8) 4 (7.5) 2.000 (0.482–8.295) 0.624 9 (13.8) 8 (13.1) 0.728 (0.215–2.459) 0.514
 Moderate 118 (79.7) 42 (79.2)    39 (60.0) 42 (68.9)   
 High 14 (9.5) 7 (13.2)    17 (26.2) 11 (18.0)   
Locationc         
 Proximal 58 (37.9) 29 (50.9) 0.589 (0.319–1.089) 0.090 60 (89.6) 54 (87.1) 1.270 (0.432–3.735) 0.664
 Distal 95 (62.1) 28 (49.1)    7 (10.4) 8 (12.9)   
Histological Typed         
 Non-Mucinous 140 (90.3) 49 (84.5) 1.714 (0.705–4.167) 0.230 76 (66.7) 73 (75.3) 0.658 (0.360–1.202) 0.172
 Mucinous 15 (9.7) 9 (15.5)    38 (33.3) 24 (24.7)   
MMR Protein Status         
 Intact 143 (97.9) 55 (98.2) 0.867 (0.088–8.511) 0.902 21 (18.6) 9 (9.1) 2.283 (0.992–5.251) 0.048
 Deficient 3 (2.1) 1 (1.8)    92 (81.4) 90 (90.9)   
MMR Germline Mutation         
 No 157 (99.4) 58 (100.0) 0.730 (0.673–0.792) 0.544 89 (76.1) 74 (74.7) 1.074 (0.577–1.999) 0.822
 Yes 1 (0.6) 0 (0.0)    28 (23.9) 25 (25.3)   
MLH1 Methylation         
 Unmethylated 143 (96.0) 52 (100.0) 0.733 (0.674–0.798) 0.142 68 (58.1) 42 (42.4) 1.883 (1.095–3.238) 6.72x10-4
 Methylated 6 (4.0) 0 (0.0)    49 (41.9) 57 (57.6)   
BRAF V600E Mutation         
 No 141 (92.2) 51 (91.1) 1.152 (0.387–3.431) 0.799 70 (63.1) 50 (52.6) 1.537 (0.088–2.683) 0.130
 Yes 12 (7.8) 5 (8.9)    41 (36.9) 45 (47.4)   
CIMP Status         
 Negative 100 (96.2) 33 (84.6) 4.545 (1.208–17.100) 0.016 50 (61.7) 29 (47.5) 1.780 (0.908–3.489) 0.092
 Positive 4 (3.8) 6 (15.4)    31 (38.3) 32 (52.5)   
Survival Status         
 Alive 110 (69.6) 35 (60.3) 1.475 (0.790–2.755) 0.221 78 (66.7) 70 (70.7) 0.829 (0.464–1.478) 0.524
 Deceased 48 (30.4) 23 (39.7)    39 (33.3) 29 (29.3)   
  1. aOdds ratio and 95 % confidence interval for methylated versus unmethylated
  2. bOR and 95 % CI given for lowest stage/grade versus highest stage/grade
  3. cProximal tumor location includes lesions up to and including the splenic flexure
  4. dMucinous histology includes the presence of any mucin within the tumor stroma